Compare Citius Pharmaceuticals Inc (CTXR) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while YieldMax TSLA Option Income Strategy ETF trades at $21.86. The key difference: Citius Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CTXR | TSLY | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $48.25 |
52-Week Low | $0.48 | $20.49 |
Enterprise Value | $16.23M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
